Figure 3. A combination therapy of alisertib plus VCR plus PI3Kα inhibition displays strong anti-proliferative activity in a PTCL mouse xenograft model.
A PTCL mouse xenograft model (CRL-2396 cells in BALB/c) evaluating AK + PI3Kα inhibition. There was a significant decrease in mean tumor burden between control versus alisertib alone on day 16 (mean decrease of 497mm3, p=0.012), versus the combination of alisertib + MLN1117 (mean decrease of 1288mm3 on day 16, p<0.001) on days 13, 16 and 20 (A). All treatments were well tolerated with no body weight changes except on day-16 there was only significant changes between negative control group and alisertib as a single agent group with p=0.043 (B).